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Abstract
Introduction: Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit.
Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Although the response rate in patients treated with imatinib mesylate in prospective clinical studies is above 50%,
a complete response is very rare. We report the case of a patient with a gastric gastrointestinal stromal tumor who
had a pathological complete response after neoadjuvant treatment with imatinib mesylate.
Case presentation: We report the case of a 54-year-old Arab woman with a gastrointestinal stromal tumor who
had a pathological complete response after neoadjuvant treatment with imatinib mesylate.
Conclusion: The pathological examination of our patient documented a complete pathological response after
imatinib therapy. Recently, it has been confirmed that the kinase genotype of KIT and platelet-derived growth factor
receptor a can accurately predict a good response to imatinib mesylate therapy. We propose that this patient had
a mutation conferring high sensitivity to imatinib mesylate.
Introduction
A gastrointestinal stromal tumor (GIST) is a neoplasm
exhibiting, in most cases, mutations of c-kit. Imatinib
mesylate (IM) is the standard treatment for patients
who have advanced GISTs, and has recently become the
standard treatment in the adjuvant setting as well, but
not all patients benefit equally. Although the response
rate in patients treated with IM in prospective clinical
studies is above 50% [1], complete response is rare. We
report a case of a patient with a GIST who had a patho-
logical complete response after neoadjuvant treatment
with IM.
Case presentation
A 54-year-old Arab woman presented with a four-
month history of epigastralgia and anemia. The endo-
scopic findings of an examination of the patient’s
stomach revealed an ulcerative tumor of the fundus,
from which the guided biopsy yielded a spindle cell neo-
plasm with positive immunohistochemical staining using
monoclonal antibodies against CD117 (c-kit). The mor-
phologic (Figure 1) and immunohistochemical features
of the tumor were consistent with GIST. The molecular
biology examination was not done. The abdominal com-
puted tomography scan revealed a heterogeneous mass
of the gastric lesser curvature measuring 11 cm × 9 cm
× 7.5 cm (Figure 2). The tumor was unresectable; hence
IM was indicated at the dose of 400 mg/day. The
patient received six months of treatment with IM, which
was well tolerated. A radiology-based major response
was obtained, thus making the tumor resectable (Figure
3). Fluorodeoxyglucose positron emission tomography
(FDG-PET) has proved to be highly sensitive in the
early assessment of tumor response. Unfortunately, the
patient did not undergo FDG-PET, because it is not
available in Morocco. The patient received a partial gas-
trectomy. The margins of the gastric resection were free
of neoplasm.
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specimen (Figure 4). The patient received one year of
IM therapy after the surgery. The patient was in com-
plete remission nine months after the end of IM
therapy.
Discussion
The management of GIST is carried out using a multi-
disciplinary approach. Standard treatment of localized
GIST is complete surgical excision associated (or not)
with adjuvant imatinib therapy. If R0 resection is not
feasible, or if it can be achieved through less mutilating
surgery in the case of cytoreduction, imatinib pretreat-
ment is recommended [2,3]. The benefit of adjuvant
imatinib therapy after neoadjuvant therapy is still in
exploration. To the best of our knowledge, no studies
evaluating this strategy have been reported in the litera-
ture. Therefore, our case illustrates complete remission
after adjuvant therapy in a patient who received IM as a
neoadjuvant treatment. Complete pathological response
in resection specimen is rarely reported. After a wide
study of the literature, only nine clinical cases have been
published of reports of complete pathologic response
after imatinib therapy in locally advanced or metastatic
GIST [4,5]. Mutational analysis (KIT/platelet-derived
growth factor receptor a (PDGFRA) receptor mutations)
has predictive value for sensitivity to molecular targeted
therapy as well as prognostic value, so that its inclusion
in the diagnostic work-up of all GISTs is recommended
[2]. Patients with exon 11 mutations of KIT have been
Figure 1 Histological study revealing spindle cells (original
magnification, ×40).
Figure 2 Computed tomographic scan revealing a large gastric
tumor.
Figure 4 Total disappearance of tumor cells in the resected
specimen after six months of imatinib treatment (original
magnification, ×40).
Figure 3 Computed tomographic scan showing a major
radiological response after six months of imatinib treatment.
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patients with exon 9 mutations of KIT [6]. We suppose
that our patient had a mutation which confers a high
sensitivity to IM. The mutational analysis in our patient
will be done later in our institution’s molecular labora-
tory. The clinical benefit of IM can also be correlated to
IM plasma levels in patients with unresectable or meta-
static GISTs, as well as a previous study [7] that sug-
gests that a low steady-state plasma level of IM at day
29 after the initiation of IM treatment (<1100 ng/mL)
might contribute to drug failure in patients with
advanced GISTs. Mutational analysis may help to
exclude patients with a less sensitive mutational status
(for example, PDGFRA D 8 4 2 Vm u t a t i o n s )f r o mI M
therapy or to tailor a therapy [2] so that it may also
help clinicians to make a decision regarding whether to
perform surgery or administer neoadjuvant therapy for
resectable GISTs.
Conclusion
The pathological examination of our patient documen-
ted a complete response after IM therapy. Recently, it
has been confirmed that the kinase genotypes of KIT
and PDGFRA a can accurately predict a good response
to IM therapy. We propose that this patient had a muta-
tion conferring high sensitivity to IM.
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